Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 577 Triple Negative Breast Neoplasms 125 Neoplasm Metastasis 50 Breast Neoplasms, Male 28 Ovarian Neoplasms 26 Neoplasms 26 Inflammatory Breast Neoplasms 22 Carcinoma, Non-Small-Cell Lung 19 Stomach Neoplasms 14 Endometrial Neoplasms 11 Carcinoma, Ductal, Breast 11 Carcinoma, Ovarian Epithelial 10 Pancreatic Neoplasms 9 Colorectal Neoplasms 9 Melanoma 8 Lung Neoplasms 8 Parkinson Disease 4, Autosomal Dominant Lewy Body 7 HER2-positive Breast Cancer 7 Squamous Cell Carcinoma of Head and Neck 6 Prostatic Neoplasms 6 Esophageal Neoplasms 6 Carcinoma, Renal Cell 6 Uterine Cervical Neoplasms 5 Urinary Bladder Neoplasms 4 Brain Neoplasms 4 Anatomic Stage I Breast Cancer AJCC v8 4 Advanced Breast Cancer 4 Small Cell Lung Carcinoma 3 Sarcoma 3 Recurrence 3

Interventions

Lapatinib 2 ribociclib 1 Trastuzumab 1 Paclitaxel 1 Letrozole 1 Goserelin 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Osteitis Deformans × Paclitaxel × Breast × Clear all

NCT00553358 2021-09-21

Neo ALTTO

Novartis

Phase 3 Completed

455 enrolled 34 charts

Breast Neoplasms, Osteitis Deformans

Data powered by HemOnc (CC BY 4.0) Colophon ⚡